Orthofix Medical Inc. $OFIX Position Raised by Engine Capital Management LP

Engine Capital Management LP raised its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 8.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,741,390 shares of the medical device company’s stock after purchasing an additional 290,646 shares during the period. Orthofix Medical makes up approximately 11.6% of Engine Capital Management LP’s holdings, making the stock its largest holding. Engine Capital Management LP owned approximately 9.59% of Orthofix Medical worth $61,022,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Juniper Investment Company LLC grew its stake in shares of Orthofix Medical by 123.5% in the fourth quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company’s stock worth $33,824,000 after purchasing an additional 1,070,656 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Orthofix Medical by 31.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company’s stock valued at $11,515,000 after acquiring an additional 159,177 shares in the last quarter. Nuveen LLC bought a new stake in Orthofix Medical during the 1st quarter valued at approximately $1,445,000. Soleus Capital Management L.P. lifted its holdings in shares of Orthofix Medical by 13.1% during the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company’s stock valued at $11,984,000 after purchasing an additional 79,441 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Orthofix Medical by 421.1% during the first quarter. Assenagon Asset Management S.A. now owns 72,226 shares of the medical device company’s stock valued at $1,178,000 after purchasing an additional 58,366 shares during the last quarter. 89.76% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of the business’s stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the completion of the sale, the insider directly owned 46,322 shares in the company, valued at approximately $486,844.22. The trade was a 7.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Barrington Research upgraded shares of Orthofix Medical to a “strong-buy” rating and set a $16.00 target price for the company in a report on Monday, June 23rd. JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a report on Friday, June 6th. Finally, Wall Street Zen upgraded shares of Orthofix Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $21.50.

Orthofix Medical Price Performance

Shares of OFIX opened at $14.75 on Thursday. The firm has a market cap of $582.54 million, a PE ratio of -4.65 and a beta of 0.86. The company has a current ratio of 2.67, a quick ratio of 1.50 and a debt-to-equity ratio of 0.38. The firm has a fifty day simple moving average of $12.40 and a two-hundred day simple moving average of $13.43. Orthofix Medical Inc. has a 1-year low of $10.24 and a 1-year high of $20.73.

Orthofix Medical (NASDAQ:OFIX) last announced its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). The company had revenue of $203.12 million for the quarter, compared to analysts’ expectations of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.